- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.11. | Moderna blueprints $140M plant in bid to bring end-to-end mRNA production to US | ||
| 19.11. | Novartis maps out plan for 'flagship' production hub in NC, eyes 700 hires | ||
| 19.11. | Agios readies FDA push in sickle cell disease despite mixed ph. 3 results, shares plummet | ||
| 19.11. | Celltrion to widen US manufacturing reach with $478M investment at former Lilly plant | ||
| 19.11. | After Lundbeck's surprise bid, Alkermes sweetens deal to acquire Avadel | ||
| 18.11. | Arrowhead strikes true with 1st FDA approval of genetic disorder drug, but Ionis competition looms | ||
| 18.11. | Sackler family, Purdue Pharma's $7.4B settlement plan wins bankruptcy judge's approval | ||
| 18.11. | Avadel views Lundbeck's $2.4B buyout offer as 'superior,' kicking the ball back to Alkermes' court | ||
| 18.11. | Merck advances Winrevair in subset of heart failure patients | ||
| 18.11. | FDA takes issue with AstraZeneca TV ad, citing 'misleading impression' of Farxiga indications | ||
| 18.11. | Regeneron pledges $2B to convert former magazine factory into drug plant: NY governor | ||
| 17.11. | Cytokinetics steps into Bristol Myers' shoes, funding heart registry ahead of commercial clash | ||
| 17.11. | After delay, Sandoz's biosimilar Tyruko launches in US to pressure Biogen's blockbuster MS med Tysabri | ||
| 17.11. | Novo unveils newly reduced self-pay prices for Wegovy, Ozempic after White House deal | ||
| 17.11. | Trump relents on Swiss tariffs, knocking rate on pharmaceuticals and other goods down to 15% | ||
| 17.11. | Jazz's HER2 drug Ziihera chalks up another win with 'practice changing' phase 3 result | ||
| 14.11. | FDA restricts Sarepta's gene therapy Elevidys after Duchenne patient deaths | ||
| 14.11. | Otsuka's HAE med Dawnzera, Lilly's oral SERD Inluriyo among drugs scoring EU endorsements | ||
| 14.11. | LB Pharmaceuticals, Celldex hire commercial chiefs as launch plans ramp up | ||
| 14.11. | Organon and Henlius' Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod | ||
| 14.11. | Survey reveals 'cardiology deserts' at heart of Amgen-backed campaign | ||
| 14.11. | Lundbeck disrupts Alkermes' planned $2.1B purchase of Avadel with higher bid | ||
| 14.11. | Biopharma industry gathers momentum in Q3 | ||
| 14.11. | Fierce Pharma Asia-Pfizer's PD-1xVEGF trials; ivonescimab's 1st survival win; Lilly's deal spree | ||
| 13.11. | Bavarian Nordic board chair exits in aftermath of failed private equity takeover |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .